THYROLAR-0.5
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-0.5 is an oral tablet containing a combination of thyroid hormones (levothyroxine and liothyronine) approved in 1969 for thyroid hormone replacement therapy. The drug works by supplementing deficient thyroid hormone levels in patients with hypothyroidism and related thyroid disorders. It represents a fixed-ratio combination approach to thyroid hormone therapy.
LOE Approaching
As an aging product with LOE approaching, this brand likely operates with a lean, maintenance-focused team focused on defending market share against generic and branded competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-0.5 offers limited career growth opportunities as a mature product in LOE stage with minimal linked job openings. Roles available are primarily defensive in nature, focused on market maintenance and generic competition management rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on THYROLAR-0.5 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.